MedTrace Logo

Metoprolol and Formoterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT00288548 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2006-02-20

No results posted yet for this study

Summary

We want to study the effect of the combination of metoprolol (a beta-blocker) with formoterol (a beta-agonist) on long function in patients with Chronic Obstructive Pulmonary Disease (COPD). There are more and more clues that a beta-blocker, when well chosen and in the right dosage, won't harm the long function in patients with COPD. Since a beta-blocker can be a valuable addition to treating patients with heart problems we would like to see if this category of medication can be available for COPD patients in the future.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

Metoprolol

Sponsors & Collaborators

  • Martini Hospital Groningen

    lead OTHER

Principal Investigators

  • René Aalbers, MD, PhD · Martini Hospital Groningen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-02-28

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00288548 on ClinicalTrials.gov